

Goertek (002241 CH)

1Q24 earnings back on track; Positive on VR/AR/gaming recovery in FY24/25E

Goertek's 1Q24 revenue/attributed net profit of -20%/+257% YoY was largely expected by the market. 1Q24 revenue weakness was due to softer demand of gaming console products, while earnings improvement was driven by low base in 1Q23 and GPM recovery to 9.2% in 1Q24 (vs 7.0% in 1Q23). Looking into FY24E, we expect Goertek's earnings will continue to improve QoQ given better AR/VR/gaming demand and overall GPM recovery. In longer term, we believe Goertek is well-positioned to capture opportunities in AR/VR product launches from major players such as Meta, Sony, Google, Samsung and Huawei. Maintain BUY with TP of RMB17.56, based on 25x FY24E P/E (7-yr hist avg).

■ **1Q24 sales weakness mostly expected.** Goertek reported 1Q24 revenue/net profit of -20%/+257% YoY, largely in-line with expectations. Earnings improvement was mainly due to better GPM and low base in 1Q23. 1Q GPM improved YoY to 9.2% (vs. 7.0% in 1Q23), boosted by better utilization and cost management. We believe the weak 1Q24 revenue was mainly due to soft demand of Goertek's multiple gaming/AR/VR products, such as Meta Quest 3 and Sony PS 5. We expect Goertek's blended GPM will continue to recover to 10.5%/10.5% in FY24/25E (vs 8.9% in FY23), given improving utilization and continued improvement in hearable product margin.

■ **2024/25 Outlook: Riding on "AI+XR" trend, PS5/Quest 3 ramp-up and gaming recovery.** In addition to recovery in hearable product segment, we believe Apple's Vision Pro MR product launch will boost AR/VR/XR industry development, and Goertek is well-positioned to capture the opportunities from AR/VR/XR product launches from major players such as Meta, Sony Google, Samsung and Huawei. Overall, we expect Goertek's FY24E revenue/net profit to deliver +1%/+120% YoY growth.

■ **Maintain BUY.** We think Goertek's industry leadership and product roadmap in XR/acoustics/gaming segments will allow it to benefit from industry recovery and MR product cycle in FY24/25E. We keep our FY24/25E EPS estimates and TP of RMB17.56, based on 25x FY24E P/E (7-yr hist avg). Maintain BUY. Upcoming catalysts include new XR product launches and continued margin recovery.

Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	104,894	98,574	99,533	105,413	111,962
YoY growth (%)	34.1	(6.0)	1.0	5.9	6.2
Net profit (RMB mn)	1,749.2	1,088.1	2,388.8	2,599.7	2,857.3
EPS (Reported) (RMB)	0.52	0.32	0.70	0.76	0.84
YoY growth (%)	(59.7)	(38.5)	119.5	8.8	9.9
Consensus EPS (RMB)	N/A	N/A	0.74	0.85	1.04
P/E (x)	30.0	48.7	22.2	20.4	18.6
P/B (x)	1.8	1.7	1.6	1.5	1.4
Yield (%)	0.6	0.6	0.7	0.7	0.8
ROE (%)	6.0	3.5	7.3	7.4	7.6

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price RMB17.56
 (Previous TP RMB17.56)
Up/Downside 12.7%
Current Price RMB15.59

China Technology

Alex NG
 (852) 3900 0881
 alexng@cmbi.com.hk

Claudia LIU
 claudialiu@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	53,317.8
Avg 3 mths t/o (RMB mn)	1,150.4
52w High/Low (RMB)	21.01/14.42
Total Issued Shares (mn)	3420.0

Source: FactSet

Shareholding Structure

Goertek Group	14.8%
Jiang Bin	8.4%

Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	-7.8%	-8.8%
3-mth	-8.0%	-14.4%
6-mth	-9.8%	-11.5%

Source: FactSet

12-mth Price Performance



Source: FactSet

Related reports:

- Goertek (002241 CH) - Focus on VR/AR/gaming business and margin recovery in FY24/25E-16 Apr 2024 ([link](#))
- Goertek (002241 CH) - 3Q23 weakness in-line; Margin recovery on track into 4Q/ FY24E-30 Oct 2023 ([link](#))
- Goertek (002241 CH) - 1H23 weakness in-line; Lower TP on slower demand recovery- 30 Aug 2023 ([link](#))

1Q24 results review

Figure 1: 1Q24 results review

RMB mn	FY22	1Q23	2Q23	3Q23	4Q23	FY23	1Q24
Revenue	104,894	24,122	21,050	28,775	24,626	98,574	19,312
...YoY	34%	20%	-10%	-6%	-20%	-6%	-20%
Cost of sales	(93,233)	(22,439)	(19,438)	(25,856)	(22,020)	(89,753)	(17,536)
Gross profit	11,661	1,683	1,612	2,919	2,606	8,821	1,776
GPM (%)	11.1%	7.0%	7.7%	10.1%	10.6%	8.9%	9.2%
...YoY	5%	-39%	-44%	-29%	36%	-24%	6%
SG&A	(2,843)	(698)	(346)	(759)	(928)	(2,731)	(609)
...% of rev	2.7%	2.9%	1.6%	2.6%	3.8%	2.8%	3.2%
R&D	(5,227)	(961)	(1,081)	(1,300)	(1,373)	(4,716)	(825)
...% of rev	5.0%	4.0%	5.1%	4.5%	5.6%	4.8%	4.3%
Operating profit	1,610	(17)	268	486	172	909	384
OPM (%)	1.5%	-0.1%	1.3%	1.7%	0.7%	0.9%	2.0%
...YoY	-66%	-102%	-80%	-75%	-107%	-44%	2299%
Net profit	1,749	106	316	470	196	1,088	380
NPM (%)	1.7%	0.4%	1.5%	1.6%	0.8%	1.1%	2.0%
...YoY	-59%	-88%	-73%	-73%	-109%	-38%	257%

Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	99,533	105,413	111,962	102,930	113,977	127,017	-3%	-8%	-12%
Gross Profit	10,441	11,033	11,688	10,585	11,926	13,091	-1%	-7%	-11%
Operating Profit	2,736	3,015	3,328	2,912	3,508	3,809	-7%	-16%	-16%
Net profit	2,425	2,676	2,958	2,549	3,141	3,540	-6%	-17%	-19%
EPS (RMB)	0.71	0.79	0.87	0.74	0.85	1.04	-5%	-10%	-19%
Gross Margin	10.5%	10.5%	10.4%	10.3%	10.5%	10.3%	0.2 ppt	0 ppt	0.1 ppt
Operating Margin	2.7%	2.9%	3.0%	2.8%	3.1%	3.0%	-0.1 ppt	-0.3 ppt	-0.1 ppt
Net Margin	2.4%	2.5%	2.6%	2.5%	2.8%	2.8%	-0.1 ppt	-0.3 ppt	-0.2 ppt

Source: Bloomberg, CMBIGM estimates

Figure 3: P&L forecast

RMB mn	FY21	FY22	FY23	FY24E	FY25E	FY26E
Revenue	78,221	104,894	98,574	99,533	105,413	111,962
...YoY	35%	34%	-6%	1%	6%	6%
Cost of sales	(67,168)	(93,233)	(89,753)	(89,093)	(94,380)	(100,274)
Gross profit	11,054	11,661	8,821	10,441	11,033	11,688
GPM (%)	14.1%	11.1%	8.9%	10.5%	10.5%	10.4%
...YoY	19%	5%	-24%	18%	6%	6%
SG&A	(2,397)	(2,843)	(2,731)	(2,727)	(2,878)	(3,023)
...% of rev	3.1%	2.7%	2.8%	2.7%	2.7%	2.7%
R&D	(4,170)	(5,227)	(4,716)	(4,867)	(5,060)	(5,262)
...% of rev	5.3%	5.0%	4.8%	4.9%	4.8%	4.7%
Operating profit	4,683	1,610	909	2,696	2,930	3,217
OPM (%)	6.0%	1.5%	0.9%	2.7%	2.8%	2.9%
...YoY	44%	-66%	-44%	197%	9%	10%
Net profit	4,275	1,749	1,088	2,389	2,600	2,857
NPM (%)	5.5%	1.7%	1.1%	2.4%	2.5%	2.6%
...YoY	50%	-59%	-38%	120%	9%	10%

Source: Company data, CMBIGM estimates

Valuation

Maintain BUY with TP of RMB17.56


Our TP of RMB17.56 is based on 25x FY24E P/E (7-year hist. avg.). Overall, we believe Goertek's industry leadership and product roadmap in TWS/XR/acoustics/gaming segments will allow the company to benefit from industry recovery and market share gain in FY24/25E. Upcoming catalysts include new XR product launches and continued margin recovery.

Figure 4: Peers' valuation

Company	Ticker	Rating	Market Cap US\$(mn)	Price (LC)	TP (LC)	Up/ Down -side	P/E (x)		P/B (x)		ROE (%)	
							FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
A-listed components												
Goertek	002241 CH	BUY	7,352	15.59	17.6	13%	48.7	22.2	1.7	1.6	3.5	7.0
Luxshare	002475 CH	BUY	28,521	28.79	46.6	62%	18.7	14.8	2.9	2.4	15.6	16.4
O-film	002456 CH	NR	4,123	9.17	NA	NA	-	43.1	-	6.5	(9.9)	12.3
Sunway	300136 CH	NR	2,492	18.66	NA	NA	23.4	18.3	2.5	2.2	10.5	11.5
BOE	000725 CH	NR	22,518	4.37	NA	NA	48.0	25.3	1.2	1.2	1.9	4.8
Hans Laser	002008 CH	NR	2,925	20.14	NA	NA	23.0	15.9	1.4	1.3	6.2	8.0
Lens Tech	300433 CH	NR	9,608	13.97	NA	NA	22.5	17.6	1.5	1.4	6.8	8.3
Everwin	300115 CH	NR	1,731	10.42	NA	NA	72.9	18.5	2.2	1.9	2.2	10.3
Average							36.7	22.0	1.9	2.3	4.6	9.8
H-listed components												
FIT Hon Teng	6088 HK	BUY	2,207	2.37	2.4	2%	16.8	10.8	0.8	0.8	5.1	7.6
AAC Tech	2018 HK	HOLD	3,919	25.60	22.4	-12%	36.4	20.0	1.2	1.2	3.3	5.8
Sunny Optical	2382 HK	HOLD	5,321	38.00	47.3	25%	33.7	27.5	1.6	1.6	4.8	5.7
Tongda	698 HK	BUY	97	0.08	0.1	79%	(0.6)	3.4	0.1	0.1	(17.6)	3.1
BYDE	285 HK	BUY	7,239	25.15	46.5	85%	12.6	9.2	1.7	2.7	13.7	29.0
Q tech	1478 HK	BUY	499	3.30	3.9	19%	11.8	9.0	0.7	0.7	6.1	7.6
TK Group	2283 HK	BUY	162	1.52	2.8	84%	6.1	4.5	0.7	0.7	12.3	15.3
SMIC	981 HK	NR	23,360	15.58	NA	NA	18.1	33.7	0.8	0.8	4.5	2.3
YOFC	6869 HK	NR	1,994	9.24	NA	NA	5.4	6.0	0.6	0.6	11.8	10.1
Cowell	1415 HK	NR	1,918	17.60	NA	NA	29.2	18.7	4.5	3.7	14.4	21.9
Average							17.0	14.3	1.3	1.3	5.8	10.8


Source: Bloomberg, CMBIGM estimates.

Figure 5: 12M forward P/E band



Source: Bloomberg, CMBIGM

Figure 6: 12M forward P/B band



Source: Bloomberg, CMBIGM

Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	78,221	104,894	98,574	99,533	105,413	111,962
Cost of goods sold	(67,168)	(93,233)	(89,753)	(89,093)	(94,380)	(100,274)
Gross profit	11,054	11,661	8,821	10,441	11,033	11,688
Selling expense	(445)	(548)	(528)	(537)	(580)	(616)
Admin expense	(1,952)	(2,295)	(2,203)	(2,190)	(2,298)	(2,407)
R&D expense	(4,170)	(5,227)	(4,716)	(4,867)	(5,060)	(5,262)
Other income	467	373	373	373	373	373
Other expense	(271)	(1,797)	282	(117)	(117)	(122)
Investment gain/loss	469	(36)	(73)	(73)	(73)	(73)
Other gains/(losses)	(80)	(105)	114	114	114	114
EBIT	4,683	1,610	909	2,696	2,930	3,217
Net Interest income/(expense)	(167)	(149)	(352)	(200)	(200)	(200)
Other income/expense	(77)	144	(118)	(118)	(118)	(118)
Pre-tax profit	4,606	1,509	791	2,578	2,812	3,098
Income tax	(299)	282	228	(258)	(281)	(310)
After tax profit	4,307	1,791	1,019	2,320	2,531	2,789
Minority interest	32	42	(69)	(69)	(69)	(69)
Net profit	4,275	1,749	1,088	2,389	2,600	2,857

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Current assets	35,162	45,563	40,041	58,228	45,766	65,400
Cash & equivalents	10,049	12,683	14,737	23,512	17,155	26,999
Account receivables	11,949	14,444	12,573	16,162	14,253	18,033
Inventories	12,082	17,349	10,795	16,618	12,422	18,432
Prepayment	98	51	255	255	255	255
Financial assets at FVTPL	119	339	587	587	587	587
Other current assets	850	698	1,094	1,094	1,094	1,094
Non-current assets	25,917	31,613	33,703	37,206	39,747	41,997
PP&E	20,250	23,884	24,377	27,880	30,421	32,671
Deferred income tax	495	1,370	1,609	1,609	1,609	1,609
Investment in JVs & assos	437	361	760	760	760	760
Intangibles	3,094	3,301	3,896	3,896	3,896	3,896
Goodwill	17	17	605	605	605	605
Financial assets at FVTPL	466	699	591	591	591	591
Other non-current assets	652	1,663	1,865	1,865	1,865	1,865
Total assets	61,079	77,176	73,744	95,434	85,514	107,397
Current liabilities	29,803	42,721	33,442	52,609	40,548	60,071
Short-term borrowings	4,285	7,121	5,214	7,214	9,214	11,214
Account payables	21,272	30,599	22,121	39,288	25,227	42,750
Tax payable	357	285	121	121	121	121
Other current liabilities	2,822	3,676	4,767	4,767	4,767	4,767
Accrued expenses	1,067	1,040	1,220	1,220	1,220	1,220
Non-current liabilities	3,345	4,197	8,775	8,775	8,775	8,775
Long-term borrowings	2,204	2,206	6,631	6,631	6,631	6,631
Bond payables	210	471	518	518	518	518
Deferred income	390	816	758	758	758	758
Other non-current liabilities	540	705	867	867	867	867
Total liabilities	33,148	46,919	42,217	61,384	49,323	68,846
Share capital	3,416	3,420	3,420	3,420	3,420	3,420
Retained earnings	9,478	10,281	8,998	8,998	8,998	8,998
Other reserves	16,725	18,083	18,670	21,192	23,334	25,694
Total shareholders equity	27,931	30,258	31,528	34,050	36,191	38,551
Minority interest	604	766	717	717	717	717
Total equity and liabilities	61,079	77,176	73,744	95,434	85,514	107,397

CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	4,606	1,509	791	2,578	2,812	3,098
Depreciation & amortization	2,918	3,651	4,069	2,557	2,959	3,250
Tax paid	(299)	282	228	(258)	(281)	(310)
Change in working capital	1,186	924	2,230	7,755	(7,956)	7,734
Others	187	1,951	834	200	200	200
Net cash from operations	8,598	8,317	8,152	12,833	(2,266)	13,973
Investing						
Capital expenditure	(6,962)	(8,090)	(6,950)	(5,500)	(5,500)	(5,500)
Acquisition of subsidiaries/ investments	(3,083)	(2,118)	(5,756)	0	0	0
Net proceeds from disposal of short-term investments	3,102	1,061	4,634	0	0	0
Others	174	71	488	0	0	0
Net cash from investing	(6,768)	(9,077)	(7,583)	(5,500)	(5,500)	(5,500)
Financing						
Dividend paid	(675)	(953)	(837)	(358)	(390)	(429)
Net borrowings	913	3,197	2,258	2,000	2,000	2,000
Proceeds from share issues	2,179	395	0	0	0	0
Others	(2,030)	(631)	354	(200)	(200)	(200)
Net cash from financing	387	2,008	1,774	1,442	1,410	1,371
Net change in cash						
Cash at the beginning of the year	6,913	9,138	10,800	13,153	21,927	15,571
Exchange difference	7	414	10	0	0	0
Cash at the end of the year	9,138	10,800	13,153	21,927	15,571	25,415
GROWTH	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Revenue	35.5%	34.1%	(6.0%)	1.0%	5.9%	6.2%
Gross profit	19.4%	5.5%	(24.4%)	18.4%	5.7%	5.9%
EBIT	43.6%	(65.6%)	(43.5%)	196.5%	8.7%	9.8%
Net profit	50.1%	(59.1%)	(37.8%)	119.5%	8.8%	9.9%
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Gross profit margin	14.1%	11.1%	8.9%	10.5%	10.5%	10.4%
Return on equity (ROE)	17.9%	6.0%	3.5%	7.3%	7.4%	7.6%
GEARING/LIQUIDITY/ACTIVITIES	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Current ratio (x)	1.2	1.1	1.2	1.1	1.1	1.1
Receivable turnover days	51.3	45.9	50.0	50.0	50.0	50.0
Inventory turnover days	57.7	57.6	57.2	57.2	57.2	57.2
Payable turnover days	104.9	101.5	107.2	107.2	107.2	107.2
VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
P/E	12.1	30.0	48.7	22.2	20.4	18.6
P/B	1.9	1.8	1.7	1.6	1.5	1.4
Div yield (%)	1.3	0.6	0.6	0.7	0.7	0.8

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.